NK cells plus rituximab for active lupus
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE) using standard criteria.
- If you have lupus nephritis, a kidney biopsy must show active inflammation (type III or IV, with or without type V) and you must have significant protein in your urine (at least 1 gram per day).
- Your lupus is still active (SLEDAI score of 8 or more) even after 3 months of treatment with steroids and other immune-suppressing drugs.
- You have not had B-cell depleting therapies (like rituximab or other anti-CD20 drugs) in the last 6 months, and no prior cell therapy (like CAR-T or CAR-NK).
- You are willing to use effective contraception for one year after the study treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
This trial tests a new type of immune cell therapy (called ES-NK cells) for people with a severe form of lupus nephritis that hasn't improved with standard treatments. The goal is to see if these cells can reduce kidney inflammation and improve lupus symptoms.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
Hear when a new Refractory Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.